Navigation Links
Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
Date:3/2/2010

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease.  

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the Company's offering of common stock described herein, including but not limited to statements regarding the proposed use of proceeds from the offering and the clinical development of Amigal™ (migalastat HCl) for Fabry disease. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should no
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Victoria Vein & Surgery Clinic ... the Astanza Duality laser in Victoria, Texas ... as well as advanced laser treatments for a variety of ... tattoo industry to provide more services for their patients. Since ... many Victoria residents get rid of ...
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is celebrating a key milestone ... Complete Knee System. ,   ... first introduced the NexGen knee system, with its innovative design ... implantations of the NexGen knee have taken place worldwide. ... demonstrates the importance of design innovation and component quality for surgeons and ...
(Date:3/27/2015)... , March 27, 2015 Report ... for leading ophthalmic drug companies  What does ... pharma ophthalmic industry ? Visiongain,s brand new report shows ... and prospects there. Our 242-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
(Date:3/29/2015)... 29, 2015 Adults who are comparing ... nationally on the web can now use the QuotesPros.com ... quotes can now be explored while researching the automated ... Learning the differences between what a term policy provides ... challenge for some men and women. Insurers typically provide ...
(Date:3/29/2015)... 29, 2015 The culmination of one of ... when the Final Four invades Lucas Oil Stadium ... been one filled with excitement, buzzer-beaters, and of course, upsets. ... superstars have been made, and future professional products have been ... to the four teams that advanced through their regional bracket ...
(Date:3/29/2015)... NY (PRWEB) March 29, 2015 ... conduct clinical trials and research, manage data results ... help their clients reach regulation standards. Contract research ... and medical device manufacturing sectors. Industry operators provide ... early- to late-stage clinical research for Food and ...
(Date:3/29/2015)... USA (PRWEB) March 29, 2015 ... Link platform provides basic health information around ... opportunity to discuss these challenges as well as ... Health Link addresses six medical conditions using evidenced ... users to engage in conversations around them., ...
(Date:3/29/2015)... California (PRWEB) March 29, 2015 ... a new transition from Pixel Film Studios, entitled TranSports. ... transitions made exclusively for Final Cut Pro X,” said ... our users the tools needed to effortlessly transition using ... introduces TranSports, a new and uniquely styled transition pack ...
Breaking Medicine News(10 mins):Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... latest issues and scientific breakthroughs in nephrology., How: ... related symposia will address this important medical issue., ... Free Communications Highlights:, TH-FC037, ... Blood Pressure. Findings from the National Health and ...
... ... States. VGI will unveil its new VerteLX™ prototypes at the upcoming Congress of Neurological ... ... VG Innovations, Inc (VGI), announced today that its VerteLoc™ Minimally Invasive Spine Stabilization system ...
... Wall posts, photo tags and questionnaires are used ... help friends and families connect; Produce for Kids, ... utilizing Facebook to assess your fresh produce personality. ... Play with Your Produce Personality Quiz helps ...
... Six federally qualified health centers (FQHC) - ... have made the switch to Sage Intergy CHC since July. ... for a fully integrated health center management and electronic health ... FQHC environment and can help these centers qualify for EHR ...
... 20 Nationally-known experts Kenneth J. Doka, PhD, MDiv, ... importance of helping grieving people cope with the holidays ... on Monday, November 16 from 1pm-2pm EST. , "Facing ... with grief during the holidays, traditionally times filled with ...
... , NASHVILLE, Tenn., Oct. 20 Aegis Health ... today that it has entered into an engagement ... Angeles to help the 354-bed facility further strengthen ... , Aegis, Physician Relationship Management program combines the ...
Cached Medicine News:Health News:Press alert for American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition 2Health News:VerteLoc™ Surpasses 750 Procedures....VerteLX™ Prototypes To Be Unveiled at Upcoming CNS Meeting in New Orleans 2Health News:Is Your Fresh Produce Personality Bananas ? 2Health News:FQHC Stigler Health and Wellness Center Chooses Sage Intergy CHC to Meet Unique Reporting Requirements 2Health News:Hospice Foundation of America Presents Webinar on 'Grief, Holidays, and Family Dynamics' 2Health News:Aegis Health Group Tapped by White Memorial Medical Center in Los Angeles to Help Strengthen Local Physician Relationships 2
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTT/1P chairs are recommended for ... clean room, static control, health care ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave ... lumbar support • Select options ... casters and glides. • BTT/1P ... following environments: industry, education, laboratory, ...
Medicine Products: